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Abstract Living cells communicate with their microenvi-
ronment and exchange information through signaling path-
ways in order to carry out most biological processes. The
CCN family of proteins has the ability to coordinate the
extracellular and intracellular signaling pathways and
epithelial-stromal cross-talks. CCN proteins have been
shown to play roles in multiple processes including cancer,
either as tumor suppressors or oncogenes. Particularly, loss
of CCN6 expression has been reported in highly aggressive
breast cancer types, especially in inflammatory breast
cancer and breast cancer with axillary lymph node
metastasis. Recent findings can better explain the biological
relevance of CCN6 as a tumor suppressor protein in breast
tumorigenesis. CCN6 loss triggers the process of epithelial
to mesenchymal transition (EMT), which converts epithe-
lial cells into migratory and invasive mesenchymal-like
cells at least in part through modulation of IGF-1 receptor
signaling pathway. Emerging data support the hypothesis
that CCN6 also exerts growth factor independent functions,
especially related to cell survival and anoikis resistance.
Thus, our work provides new insights into the functions
and mechanisms of tumor suppression exerted by CCN6 in
the breast.
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Introduction
Invasive carcinomas of the breast are largely adenocarci-
nomas characterized by invasion of adjacent tissues and
propensity to metastasize. The discovery of strategies to
halt or prevent invasion and metastasis are needed to
improve clinical outcome. Invasive carcinomas are embed-
ded in a desmoplastic stroma containing fibroblasts,
myofibroblasts, immune system cells, structural proteins,
and vessels. It has become clear in recent years that
microenvironmental signals exert a powerful influence on
the behavior of epithelial cells. Given their ability to
regulate extracellular signaling, the CCN proteins have the
potential to impact the response of cancer cells to the
extracellular stimuli.
C C N 6p r o t e i nw a sf o u n dt oh a v et u m o rg r o w t ha n d
invasion inhibitory functions in inflammatory breast
cancer and aggressive non-inflammatory breast cancer
(Huang et al. 2008; Huang et al. 2010;K l e e re ta l .2002).
Inflammatory breast cancer (IBC) is the most lethal
form of locally advanced breast cancer. It is rare,
accounting for 1–5% of all breast cancers in the United
States (Dawood and Cristofanilli 2007;V e n t u r aa n d
Merajver 2008). IBC carries a significantly worse prog-
nosis than non-inflammatory breast cancers (Levine et al.
1985). At the time of diagnosis the majority of patients
have locoregional metastasis and approximately 30%
have distant metastatic disease (Jaiyesimi et al. 1992).
Because of its rapid propensity to metastasize, IBC is a
good paradigm to study the metastatic process in breast
cancer.
Initial work on IBC showed that CCN6 messenger
RNA is downregulated in a significant number of IBC
tumors when compared to stage matched non IBC
tumors (van Golen et al. 1999). Our subsequent work
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DOI 10.1007/s12079-011-0148-9showed that CCN6 protein is downregulated in inva-
sive carcinomas with lymph node metastasis as well
(Huang et al. 2008). Of special note is that the CCN6
gene is located at chromosome 6q21-22, and loss of one
copy of the 6q arm has been shown in 23 to 80% of
human breast cancers, making it one of the most
frequent sites for allelic loss in human breast cancer
(Chappell et al. 1997; Fujii et al. 1996; Rodriguez et al. 2000).
The precise mechanism(s) underlying CCN6’s tumor
suppressor function has not been entirely elucidated.
Our efforts in this direction have shown that CCN6 can
regulate tumor growth at least in part through the
modulation of IGF-1 signaling pathway, one of the
most important growth factors in breast cancer devel-
opment and progression (Kleer et al. 2004, Zhang et al.
2005). Although we have evidence of CCN6 modulation
of IGF-1 signaling in breast epithelial cells, our recent
observations suggest that CCN6 also exerts growth factor
independent functions on benign breast epithelial cells.
These data and their relevance to human breast cancer
progression will be discussed herein.
CCN6 regulates breast cancer growth by interfering
with IGF-1 signaling pathway
Our early laboratory studies uncovered a role for CCN6 in
the control of breast tumor growth in IBC and non-IBC
tumors. The full-length CCN6 cDNA was sequenced and
cloned into an expression vector, and introduced into the IBC
cell line SUM149, which exhibit low to absent levels of
CCN6 protein (Huang et al. 2008; Kleer et al. 2002). CCN6
transfected cancer cells showed a decreased ability to grow
under anchorage independent conditions (Kleer et al. 2002).
CCN6 restoration was effective in suppressing in vivo tumor
growth in nude mice. CCN6 expression decreased the rate of
tumor formation and had a significantly favorable impact in
the survival of the mice (Kleer et al. 2002). This work
demonstrated that CCN6 has tumor suppressor functions in
IBC in vivo and in vitro.
Given the structure of CCN6 protein and its high
homology with other members of the CCN family, we
hypothesized that mammary epithelial cells may secrete
CCN6 into the extracellular medium where it may regulate
insulin like growth factor (IGF) signaling. The IGFs play a
central role in breast cancer development (Pollak 2004).
Epidemiological and clinical data show that high concen-
trations of IGF-1 in serum are associated with increased
mammographic density (one of the strongest predictors
of breast cancer risk), and also reliably predict increased
breast cancer risk specifically in premenopausal women
(Allen et al. 2005; Byrne et al. 2000; Diorio et al. 2005;
Eliassen et al. 2007; Schernhammer et al. 2005). In vitro
a n di nv i v os t u d i e sh a v es h o w nt h a tI G F sp r o m o t et h e
proliferation, survival, and metastatic ability of breast
cancer cells (Diorio et al. 2005;E l i a s s e ne ta l .2007). The
IGF-1 receptor (IGF-1R) promotes breast cancer growth
(Surmacz 2000), metastasis (Carboni et al. 2005;K i me t
al. 2007;S a c h d e ve ta l .2004), and its hyperactivation has
been linked with increased radioresistance and breast
cancer recurrence (Surmacz 2000; Turner et al. 1997).
Studies demonstrated that CCN6 protein is secreted from
breast epithelial cells and that once in the extracellular
medium is able to decrease the IGF-1-induced activation of
the IGF receptor (IGF-1R) and two of its main downstream
signaling proteins, IRS-1 and ERK-1/2, in SUM149
inflammatory breast cancer cells (Kleer et al. 2004).
CCN6-rich conditioned media slowed the growth of
SUM149 cells. It was also shown that inhibition of CCN6
in HME cells enhances IGF-1 mediated invasion and cell
proliferation (Lorenzatti et al. 2011). Taken together, this
work uncovered a previously undescribed mechanism of
CCN6 function by demonstrating that it is secreted and that
it modulates of IGF-IR signaling pathways, cellular growth
and invasion of breast cells.
New data from our lab demonstrate that the activation of
IGF-1R signaling brought about by CCN6 knockdown is
due to induction of IGF-1 levels in the extracellular
medium (Lorenzatti et al. 2011). Downregulation of
CCN6 in benign mammary epithelial cells under serum
starvation increased the levels of IGF1 mRNA as well as
the concentration of IGF-1 in the conditioned medium
compared with control levels. The levels of IGF-1 protein
in the conditioned medium and the induction of IGF-1R
and IRS1 phosphorylation by CCN6 knockdown were
higher than those exhibited by the highly aggressive breast
cancer cell line MDA-MB-231.
It is important to note that CCN3 (Nov) was also found
to modulate the effects on IGF signaling in Ewing’s
sarcoma cells (Benini et al. 2005). Recently, CCN1 (CTGF)
was shown to promote differentiation in rat fibroblasts by
enhancing the effects of IGFs (Grotendorst and Duncan
2005). Whether CCN3 or CCN1 exerts an effect on the
levels of IGF-1 in the extracellular medium has not been
reported.
CCN6 downregulation in non-tumorigenic breast
epithelial cells promotes EMT and invasion at least
in part through modulation of IGF-1 signaling
It is recognized that the acquisition of mesenchymal cell-
like features, hallmark of the process of EMT, contributes to
the progression from non-invasive lesions to invasive
carcinoma with the ability to metastasize (Hugo et al.
2007). However, very little information is currently avail-
6 W. Huang et al.able regarding the specific mechanisms leadingtoEMTin
the mammary gland. EMT of breast epithelial cells
manifests as the development of a stellate and slender
morphology and a characteristic protein expression pattern
with decreased expression of epithelial markers (e.g.
cytokeratin and E-cadherin), and elevated levels of
mesenchymal cell markers (e.g. vimentin) (Hugo et al.
2007). Although CCN proteins have been reported to exert
a variety of biological functions, it wasn’t until recently
that CCN6 knockdown was discovered to trigger a
phenotypic and gene expression program indicative of EMT.
Experiments using stable knockdown showed that down-
regulation of CCN6 results in EMT of breast epithelial cells,
with upregulation of mesenchymal proteins and down
regulation of epithelial proteins (Huang et al. 2008,Z h a n g
et al. 2005). Among these, E-cadherin was consistently
suppressed as determined using different experimental
methods and cell lines (Huang et al. 2008, Zhang et al.
2005). The association between CCN6 and E-cadherin
protein expression in human breast cancer tissues strengthens
the relevance of the experimental studies to human breast
cancer.
Several transcription factors have been implicated in the
repression of E-cadherin including zinc-finger proteins of the
Snail/Slug family, δEF1/ZEB1, SIP1, and the basic helix-
loop-helix E12/E47 factor (reviewed in (Peinado et al. 2007).
Studies have shown that Snail (SNAI1) plays a role in cancer
progression, including breast cancer (Peinado et al. 2007).
Elevated Snail expression was associated with E-cadherin
repression, tumor recurrence, metastasis and poor prognosis
in breast cancer (Moody et al. 2005; Peinado et al. 2007).
The transcriptional regulator ZEB1, by binding to the
E-boxes of the E-cadherin gene proximal promoter, has
been shown to down-regulate E-cadherin, and to induce
EMT in breast and other cancer cells including
colorectal and prostatic adenocarcinomas (Aigner et al.
2007;E g e re ta l .2005; Schmalhofer et al. 2009; Spaderna
et al. 2008). The molecular events that lead to ZEB1
overexpression have not been fully elucidated, but recent
studies implicate extracellular signaling factors including
TGFβ,T N F α, IGF-1, as well as COX-2, EGF receptor
(EGFR) and estrogen receptor activation (Graham et al.
2008; Schmalhofer et al. 2009). Interestingly, recent work
has shown that the miR-200 family of micro-RNAs is
associated with down-regulation of ZEB1 and mainte-
nance of the epithelial phenotype in the breast (Bracken et
al. 2008;B u r ke ta l .2008;K o r p a le ta l .2008;P a r ke ta l .
2008;S h i r a k i h a r ae ta l .2007).
Given this, a major focus of our research has been
devoted to elucidating the molecular basis of CCN6-
Fig. 1 Working model for CCN6 function in mammary epithelial cells
and breast cancer cells. On the basis of our data, we propose that CCN6
protein contributes to the maintenance of normal breast homeostasis.
Reduction of CCN6 protein levels, as it occurs in breast carcinomas with
metastatic propensity, increases IGF-1 levels in the extracellular medium
and results in activation of IGF-1R signaling with resulting ZEB1-
dependentEMTandinvasion,aswellascellulargrowth.CCN6reduction
can promote a growth factor independent survival program with anoikis
resistance, which depends on activation of PI3K/Akt-1 proteins, and that
can be rescued by exogenous recombinant CCN6 protein. Whether
CCN6 binds to IGF-1 in the extracellular medium, remains to be proven.
Basedonourdata,theidentificationofmeanstorestoreCCN6expression
in the mammary epithelium may serve as a therapeutic target against
breast cancer growth and invasion
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recently reported that downregulation of CCN6 induces
EMT and decreases E-cadherin expression in the breast
epithelium by increasing the levels of Snai1 and ZEB1
messenger RNA and proteins (Huang et al. 2008). Upon
CCN6 knockdown in human mammary epithelial cells,
ZEB1 and Snai1 proteins are up-regulated and recruited to
the proximal E-cadherin promoter (Huang et al. 2008).
Binding of Snai1 or ZEB1 to the promoter of the E-
cadherin gene is necessary for CCN6’s effect on E-cadherin
expression (Huang et al. 2008).
These data opened the question as to whether CCN6
regulates transcription of ZEB1 through modulation of IGF-
1 signaling pathway. Experiments using non tumorigenic
breast epithelial cells with CCN6 knockdown revealed that
addition of exogenous recombinant human CCN6 protein
blunts IGF-1 pathway activation and leads to a reduction of
ZEB1 expression. Functionally, exogenous CCN6 protein
induces an epithelial phenotype and blocks invasion in
CCN6 knockdown human mammary epithelial cells (HME)
compared to controls. Mechanistic studies utilizing gain-
and loss- of function approaches demonstrate that the effect
of CCN6 on ZEB1 is dependent on IGF-1 pathway
integrity (Lorenzatti et al. 2011).
CCN6 regulates survival of non-tumorigenic breast
epithelial cells independent of exogenous growth factors
A fundamental difference between normal and cancer cells
is their requirement for extracellular signals (Hanahan and
Weinberg 2000). While normal cells die upondeprivation of
extracellular growth factors, cancer cells have the ability to
survive in their absence (Hanahan and Weinberg 2000). We
observed that CCN6 knockdown was sufficient to increase
survival of mammary epithelial cells in serum free
conditions. This prompted us to investigate the underlying
mechanisms. Our studies showed that CCN6 blockade
confers a distinct survivaladvantage to nontumorigenicbreast
epithelial cells, MCF10A and HME (Huang et al. 2010).
CCN6 downregulation leads to growth factor-independent
survival and proliferation, and is sufficient to trigger
anchorage-independent growth of mammary epithelial cells
(Huang et al. 2010).
Anoikis, or detachment-induced apoptosis, is a protective
mechanism by which epithelial cells die upon loosing contact
with the extracellular matrix. The acquisition of anoikis
resistance has been shown to promote breast cancer
progression and metastasis by enabling cancer cells to
survive in the vascular or lymphatic channels (Douma et
al. 2004;M o r oe ta l .2009). We have found that CCN6 is a
novel regulator of anoikis in breast cancer cells. CCN6
knockdown in MCF10A and HME cells is sufficient to
prevent anoikis and promote growth under anchorage
independent conditions in the absence of exogenous growth
factors (Huang et al. 2010). Mechanistically, the growth
factor-independent survival and anoikis resistance conferred
by CCN6 knockdown require activation of the PI3K/Akt-1
signaling pathway (Huang et al. 2010). We postulate that the
induction of anoikis resistance may contribute to the
enhanced metastases observed in invasive carcinomas with
low CCN6 protein expression (van Golen et al. 1999),
(Huang et al. 2008).
Closing remarks
Of the CCN family, CCN6 (WISP3) is the least studied
member.SincethediscoverythatCCN6expressionisreduced
in a large number of invasive carcinomas of the breast, we
have devoted our efforts to elucidating its possible role as a
tumor suppressor. Figure 1 illustrates our working model for
CCN6 function in breast tumorigenesis. Our data support the
hypothesis that CCN6 maintains controlled growth and an
epithelial phenotype in the breast. Reduction of CCN6
expression results in increased levels of IGF-1 and activity
of IGF-1R signaling pathway in mammary epithelial cells.
This in turn is responsible for ZEB1-mediated EMT and
invasion, as well as enhanced cell growth. Another
consequence of CCN6 protein reduction in nontumorigenic
breast epithelial cells is the activation of a growth factor
independent survival program with anoikis resistance,
which can be overcome by exogenous CCN6 protein.
Studies aimed at pinpointing the molecular mechanism by
which CCN6 regulates these processes is an area of
important forthcoming research. Another area of investiga-
tion is on the possible relationship between CCN6 and
other CCN family members with functions in breast
tumorigenesis, especially CCN1 and CCN2, which is
currently unknown. The roles of CCN6 in the regulation
of breast cancer cell survival, EMT and invasion has
potential therapeutic implications.
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